Amyris, Inc., a vertically integrated biomanufacturing company based in Emeryville, Calif., announced that it will acquire Oobli Inc., a Davis, Calif.-based sweet protein innovator. Oobli’s fermentation-based ingredients are designed to help food and beverage brands reduce sugar without sacrificing taste.
The acquisition is intended to combine Amyris’ scientific capabilities and manufacturing depth with Oobli’s expertise in protein fermentation. Amyris said the move follows its expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil. The company described the acquisition as a strategic commercial and technology expansion that would accelerate its presence in protein- and peptide-based solutions across end markets.
Platform and portfolio
Oobli’s commercial portfolio of sweet proteins will be the first to benefit from the combined platform, according to the announcement. Oobli has spent the past decade refining a fermentation process for producing sweet proteins that are naturally found in rare fruits and berries near the equator. The company says its sweet proteins are the first of their kind in the sugar-reduction category.
According to the announcement, sweet proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors, and are metabolized by the body as protein. Oobli says this delivers sweetness without gut disruption or blood sugar spikes. The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin, respectively.
Oobli’s ingredients have FDA GRAS status as an ingredient and are FEMA GRAS-affirmed for use as a natural flavor, the announcement says. With growing consumer awareness of metabolic health and the benefits of sugar reduction, the companies position sweet proteins as a tool for brands across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery.
Executive views and closing
Amyris Chief Executive Officer Kathy Fortmann said Oobli offers a commercial and technology platform that complements Amyris’ own. She said Oobli is poised to transform how sweetness reaches the market and that Amyris aims to bring commercial scale and resources to accelerate what the company calls the sweet revolution. Fortmann also said combining Oobli’s protein expertise with Amyris’ strain engineering, manufacturing scale and commercial capabilities could broaden capabilities in food and beverage, personal care, flavor and fragrances, agriculture and beyond.
Oobli Chief Executive Officer Ali Wing said the company had long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. She said joining Amyris would give Oobli the scale and resources to pursue its ambition of making sweet proteins a global standard in sweetness solutions.
Fortmann added that Amyris has seen biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli’s platform does so by addressing sweet taste, sugar reduction and clean label at the same time. The acquisition is expected to close in the coming weeks. Amyris said all existing customer commitments and brand partnerships will continue to be honored without interruption.
